PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30642546-10	2019	Additionally, concurrent TP53 mutation demonstrated significantly shorter progression-free survival (PFS) compared with TP53 wildtype in crizotinib-alone group (median PFS: 8 vs 13 months, Hazard Ratio = 1.494, P = 0.019).	Crizotinib	137-147	tumor protein p53	Homo sapiens	25-29	
29997966-0	2018	TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.	Crizotinib	104-114	tumor protein p53	Homo sapiens	0-4	
29997966-2	2018	We analyze the impact of TP53 mutations on response to crizotinib in patients with ALK rearrangement NSCLC.	Crizotinib	55-65	tumor protein p53	Homo sapiens	25-29	
29997966-10	2018	Conclusions: TP53 mutations reduce responsiveness to crizotinib and worsen prognosis in ALK rearrangement NSCLC patients.	Crizotinib	53-63	tumor protein p53	Homo sapiens	13-17	
32871626-9	2020	Furthermore, TP53 was most frequently mutated in patients who progressed on crizotinib, and TP53 mutations were significantly associated with shorter crizotinib PFS.	Crizotinib	76-86	tumor protein p53	Homo sapiens	13-17	
32871626-9	2020	Furthermore, TP53 was most frequently mutated in patients who progressed on crizotinib, and TP53 mutations were significantly associated with shorter crizotinib PFS.	Crizotinib	150-160	tumor protein p53	Homo sapiens	92-96	
32872120-5	2020	Nevertheless, TP53 co-mutations are relatively frequent and are associated with adverse outcome of crizotinib treatment, whereas utility of next-generation ALK inhibitors in TP53-mutant tumors is still unknown.	Crizotinib	99-109	tumor protein p53	Homo sapiens	14-18	
30843662-0	2019	Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.	Crizotinib	44-54	tumor protein p53	Homo sapiens	12-16	
30843662-4	2019	The clinicopathologic features of the TP53 mutations and its impact on the effect of crizotinib treatment were analyzed.	Crizotinib	85-95	tumor protein p53	Homo sapiens	38-42	
30843662-11	2019	CONCLUSIONS: TP53 mutations, especially nondisruptive mutations, negatively affected the response to crizotinib and correlated with shorter PFS in ALK-rearranged NSCLC patients.	Crizotinib	101-111	tumor protein p53	Homo sapiens	13-17	
30642546-12	2019	Concomitant TP53 mutation correlated to unfavorable survival when receiving a single TKI crizotinib.	Crizotinib	89-99	tumor protein p53	Homo sapiens	12-16	
34552337-6	2021	The effect of the TP53 G245S mutation on crizotinib sensitivity was tested in H3122 cells.	Crizotinib	41-51	tumor protein p53	Homo sapiens	18-22	
34552337-11	2021	H3122 cells with TP53 mutant were more sensitive to crizotinib compared with control cells.	Crizotinib	52-62	tumor protein p53	Homo sapiens	17-21	
34552337-12	2021	Conclusion: A higher mutation burden and mutations in DNA repair gene, including TP53, were potentially associated with primary resistance to crizotinib in ALK-rearranged NSCLC.	Crizotinib	142-152	tumor protein p53	Homo sapiens	81-85